Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson’s Disease

• DOI: 10.1016/j.neulet.2017.11.012
• Publication Date: 2017-11-10T04:15:41Z
• Authors: Nikolaos Papagian...; Christos Koros; Maria Stamelou; Athina-Maria Simitsi; Matina Maniati; Roubina Antonelou; Dimitra Papadimit...; Georgia Dermentzaki; Marina Moraitou; Helen Michelakakis; Leonidas Stefanis
• Keywords: Pathogenesis; Synuclein

Variations of α-synuclein levels or species have been reported in Parkinson's Disease (PD). There has been little systematic examination of erythrocytes, a rich source of α-synuclein.Erythrocyte membranes were obtained from PD patients (mutation carriers in the α-synuclein gene (A53T-PD) and glucocerebrosidase gene (GBA-PD) (n=18 each), and patients without known mutations (GU-PD, n=56)), and age-/sex-matched controls (n=56). Levels of monomeric and dimeric α-synuclein were assessed using Western immunoblotting.A statistically significant increase of α-synuclein dimer and dimer to monomer ratio was found in GBA-PD and GU-PD. In contrast, dimer levels of A53T-PD were not different from controls. No difference was found in α-synuclein monomer levels.The increased α-synuclein dimer in GBA-PD and GU-PD is suggestive of an apparent systemic dysfunction causing the dimerization, and potentially oligomerization, of α-synuclein. These results may have implications for PD pathogenesis and biomarker development.